The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of...
The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of...
美國食品藥品監督管理局批准novocure的新型頭部柔性電極換能器陣列用於與Optune Gio結合治療患有多形性膠質母細胞瘤的成年人，novocure計劃在今年上半年將美國的Optune Gio用戶轉換爲新的HFE陣列。
The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of 2025 Through A Controlled Transition Plan
FDA批准novocure的新型頭部柔性電極傳感器陣列，用於與Optune Gio聯合使用，適用於膠質母細胞瘤成年患者。novocure計劃在2025年上半年通過控制過渡計劃，將美國的Optune Gio 用戶轉換爲新的HFE陣列。
Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, which disrupt the rapid cell division exhibited by cancer cells.
Optune Gio是一種可穿戴的便攜設備，產生交替電場，稱爲腫瘤治療場（TTFields），通過非侵入性可穿戴陣列傳遞。TTFields對電荷分離的癌細胞元件施加物理力量，干擾癌細胞的快速分裂。
The new HFE arrays utilize a flexible polymer material in place of the ceramic discs used in the current Optune Gio arrays, making them one-third lighter and 50% thinner.
新的HFE陣列採用柔性聚合物材料替代當前Optune Gio陣列中使用的陶瓷盤，使其重量減輕三分之一，減薄50%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間